|
**Overview**: **Immune Reconstitution Panel Panel****Introduction**: The Immune Reconstitution Panel Test is a diagnostic tool designed to analyze lymphocyte subsets including CD4 T-cell, CD8 T-cell, and CD19 B-cell counts in whole blood samples, facilitating the assessment of immune recovery. Associated with immune deficiency post-transplantation or HIV, this immunologic condition presents with frequent infections, fatigue, and severe complications like opportunistic infections if untreated, particularly in individuals with chronic immunosuppression. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs flow cytometry technology, delivering detailed immune profiling over 3-5 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in flow cytometry settings. This diagnostic falls under immune screening and targets individuals with infectious or systemic symptoms, addressing the challenge of accurate immune classification to guide antiretroviral or immunosuppressive therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its blood-based approach ensures comprehensive analysis.**Other Names**: Lymphocyte Subsets Test.**FDA Status**: FDA approved, CLIA certified for flow cytometry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by various immunology labs, this test advanced immune diagnostics by standardizing lymphocyte subset analysis.**Purpose**: The test analyzes CD4 T-cell count, CD8 T-cell count, and CD19 B-cell count to guide immune deficiency diagnosis, assess immune status, and inform treatment and prevention strategies.**Test Parameters**: Presence of CD4 T-cell count, CD8 T-cell count, and CD19 B-cell count, detected with high specificity to indicate immune activity, typically observable in whole blood at altered levels during active deficiency, with subset ratios and absolute counts assessed to determine severity and distribution, providing a comprehensive profile of immune damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected immune components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report frequent infections, fatigue, or recent immunosuppressive therapy.**Specimen**: Whole Blood 2-5 mL, collected using EDTA tubes, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade cells, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on frequent infections, fatigue, prior immune conditions, or family history of immunologic disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated deficiency including opportunistic infections, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves blood sample processing, flow cytometry analysis, and interpretation by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3-5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with clinical evaluation or viral load testing is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible immune deficiency, necessitating further investigation like viral load or immunology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the active phase.**Specialist Consultation**: Immunologists or infectious disease specialists should be consulted for case management, treatment planning, and coordination with immune programs.**Additional Supporting Tests**: HIV viral load, CD4/CD8 ratio, or clinical assessment for confirmation.**Test Limitations**: The test may produce false negatives in early deficiency or false positives in transient changes, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: CDC Guidelines 2023, Journal of Immunology 2024, Flow Cytometry 2025. |
